AbbVie Gains License Option to Cugene’s Autoimmune and Inflammatory Disease Portfolio

AbbVie Gains License Option to Cugene’s Autoimmune and Inflammatory Disease Portfolio

AbbVie has secured options to worldwide rights for several of Cugene’s interleukin-2 (IL-2) muteins, which are proteins with altered amino acid sequences that are being evaluated as potential treatments for autoimmune and inflammatory diseases.

Cugene’s lead candidate, CUG252, is designed to selectively activate immune-suppressive Treg cells while reducing undesired IL-2 activity. CUG252 is currently in a phase 1 study in healthy volunteers.

Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, plus additional payments for reaching developmental or regulatory milestones.

It will also receive separate payments if AbbVie exercises its licensing option for a particular mutein as well as sales-based milestones and tiered royalties.

Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines that harness specific immune cells to treat autoimmune disease and cancer.

May 20, 2022

https://www.fdanews.com/


0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company